Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 205

Infectious diseases can have very different effects on different people; some individuals may have virtually no symptoms from COVID-19, for example, while others are killed by the viral disease. Scientists have now learned more about one genetic mechanism that can lead to variations in immune responses in different people. The findings, which have been reported in Cell, describe a kind of tuner that can dial the immune response up or down, and has been encoded in human DNA for millions of years.

The human genome contains bits of ancient viruses known as retrotransposons, which were once able to move around the genome, like so-called jumping genes, but have since been brought under control. They are thought to compose a major part of the genome. Researchers have identified instances where retrotransposons can become active again, however, such as in some types of cancer. Now even more consequences of these trasnposons are being identified.

Read more | >

Dr. Ariel Zeleznikow-Johnston hopes to pick up the movement where Jones left off, albeit with the significant twist that his version does not require freezing. A research fellow at Melbourne’s Monash University, Zeleznikow-Johnston wrote the new book, “The Future Loves You: How and Why We Should Abolish Death,” which makes the case that cryopreservation is possible and should be more widely available. Rejecting the popular notion that death endows life with meaning as “palliative philosophy,” Zeleznikow-Johnston’s book instead argues a human’s connectome — a high-resolution map of all their brain connections — could be theoretically recorded perfectly before they die.

Once that happens, that same internal brain activity could be recreated through high-powered computers, while a new brain is grown in a vat via stem cells or some combination of the two. As such, Zeleznikow-Johnston is proposing a spiritual descendant to the cryonics movement (which he dismisses as “unscientific” and “unsubstantiated”), one where the focus is not on preserving tissues but on the “data,” so to speak, of our distinct connectomes.

“We have very strong evidence that the static structure of the neurons is enough to hold onto someone’s memories and personality.”

Read more | >

For years, researchers and clinicians have been trying to find a way to rapidly deliver oxygen to patients when traditional means of oxygenation are difficult or ineffective during critical moments of cardiac or respiratory arrest.

Sometimes, hypoxemia caused by or can be so severe that methods to boost low-oxygen levels (including the placement of a breathing tube) are ineffective. A patient can have , potentially leading to severe organ damage. Research has shown that as many as 40% of in-hospital cardiac arrests are triggered by low-oxygen levels.

After 15 years of , Boston Children’s cardiologist John Kheir, MD, and researcher Yifeng Peng, Ph.D., believe they have developed a safe and effective oxygen delivery method for those emergencies: injectable oxygen carried into the bloodstream by a rapidly dissolving gas microbubble.

Read more | >

“Everyone thinks that [after] spinal injury, all you want to do is be able to walk again. But if you’re a tetraplegic or a quadriplegic, what matters most is working hands,” she said.

Reid received the device, called ARCex, as part of a 60-person clinical trial. She and the other participants completed two months of physical therapy, followed by two months of physical therapy combined with stimulation. The results, published today in Nature Medicine, show that the vast majority of participants benefited. By the end of the four-month trial, 72% experienced some improvement in both strength and function of their hands or arms when the stimulator was turned off. Ninety percent had improvement in at least one of those measures. And 87% reported an improvement in their quality of life.

This isn’t the first study to test whether noninvasive stimulation of the spine can help people who are paralyzed regain function in their upper body, but it’s important because a trial has never been done before in this number of rehabilitation centers or in this number of subjects, says Igor Lavrov, a neuroscientist at the Mayo Clinic in Minnesota, who was not involved in the study. He points out, however, that the therapy seems to work best in people who have some ability to move below the site of their injury.

Read more | >

22q11.2 deletion syndrome (22q) raises schizophrenia risk through skull malformations linked to the Tbx1 gene, affecting cerebellar development. This highlights how non-brain factors like bone defects can influence neurological disorders.

The chromosomal disorder 22q11.2 deletion syndrome (22q) has emerged as one of the strongest risk factors for schizophrenia. Scientists at St. Jude Children’s Research Hospital identified malformed regions of the cerebellum in both laboratory models and patients with 22q, attributing these malformations to improper skull formation.

Additionally, the researchers linked the skull malformation to the loss of a single gene: Tbx1. This research highlights that neurological disorders can arise from sources outside the nervous system, such as defects in skull development. The findings were published in Nature Communications.

Read more | >

Because glucose metabolism is disrupted in several different neurodegenerative disorders, this treatment strategy also shows promise for other brain conditions.

“The beneficial effect on brain metabolism by IDO1 inhibition cuts across different types of pathology,” Andreasson said.

“It is exciting to think that this may be a more general mechanism that could be targeted in other neurodegenerative disorders, like Parkinson’s disease, where you have accumulation of a-synuclein, or ALS, where there is accumulation of tdp-43.”

Read more | >

Introduction: The lips fulfill various critical physiological roles besides being viewed as a fundamental aesthetic feature contributing to the perception of health and beauty. Therefore, any lip injury, abnormality, or congenital malformation, such as cleft lip, needs special attention in order to restore proper lip function and aesthetics. To achieve this goal, a better understanding of the complex lip anatomy, function, and biology is required, which can only be provided by basic research endeavors. However, the current lack of clinically relevant human lip cells and three-dimensional in vitro lip models, capable of replacing ethically questionable animal experimentations, represents a significant limitation in this area of research.

Methods: To address these limitations, we aimed to pioneer the introduction of immortalized healthy lip-and cleft lip-derived keratinocytes. Primary keratinocytes were isolated from patients’ samples and immortalized by introducing the catalytic domain of telomerase, combined with the targeted knockdown of the cell cycle inhibitor gene, p16INK4A. We then focused on validating the newly established cell lines by comparing their genetic stability and key phenotypic features with their primary keratinocyte counterparts.

Results: The newly established immortalized keratinocyte cell lines demonstrated genetic stability and preserved the main phenotypic characteristics of primary keratinocytes, such as cellular morphology and differentiation capacity. Three-dimensional lip models, generated using these cell lines, proved to be effective and convenient platforms for screening applications, including wound healing and microbial infection of the lip epithelium.

Read more | >

One of the most elusive challenges oncologists encounter is why some patients respond to a particular therapy while others do not. Thus, optimizing a personalized treatment regimen that gives a patient the best odds of success has become a cornerstone of cancer research. The desire to implement more individualized therapies has brought about an increasing the focus on personalized medicine. This promising approach uses specific patient characteristics, including genetic makeup, environment, and lifestyle, to develop an individualized treatment plan.

Working towards improving the speed and accuracy of genetic screening to inform personalized medicine, a team of researchers conducted a comprehensive study. The journal NPJ Precision Oncol recently published the results. The researchers meticulously investigated the gene expression of almost 800 cancer cell lines and their response to treatment. With this thorough process, the researchers identified specific genetic patterns that correlated with drug resistance.

The study identified 36 genes correlating to resistance to multiple anti-cancer drugs. The researchers calculated a score, called UAB36, based on the correlation coefficient of the 36 genes identified. This UAB36 score, a novel predictive tool, accurately forecasted resistance to tamoxifen, an anti-cancer drug used to treat some types of breast cancer and prevent cancer progression in women with ductal carcinoma in situ (DCIS).

Read more | >

HPH-15, a compound developed by Kumamoto University, reduces blood glucose and fat accumulation more effectively than metformin, with added benefits like antifibrotic properties and a safer profile. This innovation may revolutionize diabetes treatment.

Scientists at Kumamoto University have unveiled a novel compound, HPH-15, which has dual effects: reducing blood glucose levels and combating fat accumulation. This breakthrough represents a significant advancement in diabetes treatment innovation.

Type 2 diabetes, a condition affecting millions worldwide, is often accompanied by complications such as fatty liver and insulin resistance, posing challenges for current treatment methods. The research team, led by Visiting Associate Professor Hiroshi Tateishi and Professor Eiichi Araki, has identified HPH-15 as a promising alternative to existing medications like metformin.

Read more | >